In the context of acute myeloid leukemia (AML) treatment, the interface between chemotherapy and immunotherapy is at present getting closer as never before. Scientific research is oriented in overcoming the main limits of actual chemotherapeutic regimens against AML, which still accounts for a considerable number of relapsed or resistant forms. A lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently gene-modified immune cells have been considered as an alternative approach whenever chemotherapy fails to eradicate the disease. In this sense, AML is a potential suitable target for immunotherapeutic approaches, due to overexpression of several tumor antigens. Here we describe the state of the art of mAbs and cellular therapies employing engineered immune effectors, developed against specific AML antigens, in a window embracing preclinical research and translational studies to the clinical setting.

+More

antibodies engineered immune effectors immunotherapeutic cellular therapies

Sarah, Tettamanti Chiara Francesca, Magnani Andrea, Biondi Ettore, Biagi,.Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors.. 155 (1-2),43-6.

Sarah, Tettamanti Chiara Francesca, Magnani Andrea, Biondi Ettore, Biagi,"Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors." 155

Sarah, Tettamanti Chiara Francesca, Magnani Andrea, Biondi Ettore, Biagi,"Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors."